Factory 99% Bictegravir Powder CAS 1611493-60-7 Chemical Intermediate Bictegravir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A925
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Bictegravir
• CAS: 1611493-60-7
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Bictegravir
Appearance	White Powder
CAS NO.	1611493-60-7
Storage	Keep in a cool, dry, dark location

 

Bictegravir is a potent inhibitor of the HIV-1 integrase enzyme, belonging to a class of drugs known as integrase strand transfer inhibitors (INSTIs). It is developed by Gilead Sciences and is used in the treatment of HIV-1 infection.

 

1. Combination Therapy: Bictegravir is typically administered as part of a combination therapy regimen. It is combined with other antiretroviral agents, such as emtricitabine and tenofovir alafenamide, to form a complete treatment regimen for HIV-1 infection. This combination is marketed under the brand name Biktarvy®.

2. Treatment-Naïve and Experienced Patients: Bictegravir is indicated for the treatment of adults and pediatric patients weighing at least 14 kg who are either antiretroviral treatment-naïve or who have been previously treated with other antiretroviral medications. It is suitable for both initial therapy and as a switch from other regimens.

3. Single-Tablet Regimen: As part of Biktarvy®, bictegravir is formulated as a single-tablet regimen, which simplifies the treatment process and improves patient adherence.

1. Inhibition of HIV-1 Integrase: Bictegravir specifically targets and inhibits the HIV-1 integrase enzyme, which is essential for the virus to integrate its genetic material into the host cell's DNA. By blocking this process, bictegravir prevents the virus from replicating and spreading within the body.

2. Antiviral Activity: The potent antiviral activity of bictegravir effectively suppresses HIV-1 replication, leading to a reduction in viral load and an improvement in immune function. This helps to control the progression of HIV-1 infection and reduces the risk of developing AIDS-related complications.

3. High Barrier to Resistance: Bictegravir has a high genetic barrier to resistance, meaning that it is less likely to develop resistance mutations compared to other antiretroviral drugs. This contributes to its long-term efficacy and durability as a treatment option for HIV-1 infection.